✨ Free AI Report
Tango Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Tango Therapeutics, Inc.
Company Research

Tango Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Tango Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Precision oncology player targeting underserved populations with synthetic lethality approach, but dependent on clinical advancement and capital management. Early-stage biotech with validated synthetic lethality platform and advancing clinical pipeline, but pre-revenue from drug sales with negative EPS and modest market cap. Recent CEO transition and clinical-stage program dependencies present.

What is Tango Therapeutics, Inc.'s industry? Tango Therapeutics, Inc. (tangotx.com) operates in Biotechnology - Precision Oncology. AskCyborg classifies Tango Therapeutics, Inc. under Biotechnology - Precision Oncology in its company registry.

Tango Therapeutics is a clinical-stage precision oncology company focused on discovering novel drug targets for cancer treatment using synthetic lethality principles. The company develops genetically targeted therapie...

6/ 10Solid

Cyborg Score thesis

Precision oncology player targeting underserved populations with synthetic lethality approach, but dependent on clinical...

Read the full analyst-debate transcript →
Industry Biotechnology - Precision Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Tango Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Tango Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Tango Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Tango Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Tango Therapeutics, Inc. Overview

Pro stress-test →

Tango Therapeutics is a clinical-stage precision oncology company focused on discovering novel drug targets for cancer treatment using synthetic lethality principles. The company develops genetically targeted therapies aimed at specific patient populations with unmet medical needs.

Strategic Profile

Pro stress-test →

Tango leverages synthetic lethality and novel genetics-based approaches to develop medicines that take direct aim at specific tumors, including expanding into tumor suppressor gene loss and immune evasion mechanisms. The company's pipeline includes PRMT5 inhibitors for both CNS and non-CNS cancers, plus CoREST platform programs.

Competitive Landscape

Pro stress-test →

Tango competes in the precision oncology space with companies including Prelude Therapeutics, Repare Therapeutics, IDEAYA Biosciences, and FoRx Therapeutics. The competitive advantage lies in the synthetic lethality platform and patient-centric approach to genetically defined tumors.

Industry Context

Tango Therapeutics, Inc. operates in Biotechnology - Precision Oncology.

Key facts

Founded: 2017 · Headquarters: Boston, Massachusetts · Revenue: $66.5M · Market cap: $1.41B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Tango Therapeutics, Inc..

  • Core platform uses synthetic lethality principle to develop precision cancer medicines targeting genetically defined patient populations
  • Lead programs TNG462 and TNG456 are PRMT5 inhibitors in clinical development for pancreatic, lung, and brain cancers
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026CEO transition announced with Barbara Weber retiring and Malte Peters appointed successor
  • January 2026Stock trading at $10.44 with market cap of $1.41B
  • +1 moreTrack every material event for Tango Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Tango Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Precision Oncology PlatformDNA damage response inhibitors→Homologous Recombination RepairRAD51 inhibitors for precision oncology→Precision Cancer MedicineTargeted therapies for defined patient populations→

Compare Tango Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Tango Therapeutics, Inc. operates in Biotechnology - Precision Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Precision Oncology research →
NEW · MCP server

Ask your AI assistant about Tango Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Tango Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Tango Therapeutics, Inc. do this quarter?”
“Is Tango Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Tango Therapeutics, Inc. do?+
Tango Therapeutics is a clinical-stage precision oncology company focused on discovering novel drug targets for cancer treatment using synthetic lethality principles. The company develops genetically targeted therapie...
What is Tango Therapeutics, Inc.'s Cyborg Score?+
Tango Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Tango Therapeutics, Inc.'s main competitors?+
Named competitors include Precision Oncology Platform, Homologous Recombination Repair, Precision Cancer Medicine. The full competitive landscape is in the AskCyborg report.
How can I get the full Tango Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Tango Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Tango Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.